Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 14, 2026
Reporting period
Not applicable
Filed with the SEC
Jun 15, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001213900-26-068922
Filed / recorded
Jun 15, 2026, 9:24 PM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Unicycive Therapeutics, Inc.
Issuer CIK
1766140
Ticker
UNCY
Reporting person
Shalabh K. Gupta
Relationship
Director, Officer
Officer title
CEO
Security
Restricted Stock Units
Table
Derivative (Table II)
Transaction date
May 14, 2026
Transaction code
A
Shares / units
762,200
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
762,200
Ownership form
Direct
Amendment
Yes (Form 4/A)
Footnotes from the filing
Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.